Alizadeh A, Jafari B, Dastmalchi S
Adv Pharm Bull. 2023; 13(1):113-122.
PMID: 36721815
PMC: 9871275.
DOI: 10.34172/apb.2023.012.
Camp S, Marciniak A, Chiang E, Garcia A, Bittman R, Polt R
Pulm Circ. 2020; 10(1).
PMID: 32095229
PMC: 7011338.
DOI: 10.1177/2045894020905521.
Alizadeh A, Jafari B, Dastmalchi S
J Mol Graph Model. 2019; 94:107459.
PMID: 31589999
PMC: 7110456.
DOI: 10.1016/j.jmgm.2019.107459.
Chen B, Roy S, McMonigle R, Keebaugh A, McCracken A, Selwan E
ACS Chem Biol. 2015; 11(2):409-14.
PMID: 26653336
PMC: 4862402.
DOI: 10.1021/acschembio.5b00761.
Camp S, Chiang E, Sun C, Usatyuk P, Bittman R, Natarajan V
Chem Phys Lipids. 2015; 191:16-24.
PMID: 26272033
PMC: 4655823.
DOI: 10.1016/j.chemphyslip.2015.08.004.
Interaction of integrin β4 with S1P receptors in S1P- and HGF-induced endothelial barrier enhancement.
Ni X, Epshtein Y, Chen W, Zhou T, Xie L, Garcia J
J Cell Biochem. 2014; 115(6):1187-95.
PMID: 24851274
PMC: 4374432.
DOI: 10.1002/jcb.24770.
Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).
Fransson R, McCracken A, Chen B, McMonigle R, Edinger A, Hanessian S
ACS Med Chem Lett. 2013; 4(10).
PMID: 24273632
PMC: 3834958.
DOI: 10.1021/ml4002425.
Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury.
Natarajan V, Dudek S, Jacobson J, Moreno-Vinasco L, Huang L, Abassi T
Am J Respir Cell Mol Biol. 2013; 49(1):6-17.
PMID: 23449739
PMC: 3727889.
DOI: 10.1165/rcmb.2012-0411TR.
Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions.
Parrill A, Tigyi G
Biochim Biophys Acta. 2012; 1831(1):2-12.
PMID: 22982815
PMC: 3591812.
DOI: 10.1016/j.bbalip.2012.09.002.
Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.
Raje M, Knott K, Kharel Y, Bissel P, Lynch K, Santos W
Bioorg Med Chem. 2011; 20(1):183-94.
PMID: 22137932
PMC: 3748591.
DOI: 10.1016/j.bmc.2011.11.011.
Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors.
Mathews T, Kennedy A, Kharel Y, Kennedy P, Nicoara O, Sunkara M
J Med Chem. 2010; 53(7):2766-78.
PMID: 20205392
PMC: 2875079.
DOI: 10.1021/jm901860h.
FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.
Adachi K, Chiba K
Perspect Medicin Chem. 2009; 1:11-23.
PMID: 19812733
PMC: 2754916.
Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs.
Foss Jr F, Mathews T, Kharel Y, Kennedy P, Snyder A, Davis M
Bioorg Med Chem. 2009; 17(16):6123-36.
PMID: 19632123
PMC: 2793099.
DOI: 10.1016/j.bmc.2009.04.015.
Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro.
Camp S, Bittman R, Chiang E, Moreno-Vinasco L, Mirzapoiazova T, Sammani S
J Pharmacol Exp Ther. 2009; 331(1):54-64.
PMID: 19592667
PMC: 2766218.
DOI: 10.1124/jpet.109.153544.
Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist.
Zhu R, Snyder A, Kharel Y, Schaffter L, Sun Q, Kennedy P
J Med Chem. 2007; 50(25):6428-35.
PMID: 17994678
PMC: 2895489.
DOI: 10.1021/jm7010172.
Sphingosine 1-phosphate pKa and binding constants: intramolecular and intermolecular influences.
Naor M, Walker M, Van Brocklyn J, Tigyi G, Parrill A
J Mol Graph Model. 2007; 26(2):519-28.
PMID: 17467317
PMC: 2040500.
DOI: 10.1016/j.jmgm.2007.03.004.